Literature DB >> 22873503

Oxaliplatin-induced lung toxicity. Case report and review of the literature.

Tiziana Prochilo1, Chiara Abeni, Paola Bertocchi, Alberto Zaniboni.   

Abstract

Rapidly developing pulmonary fibrosis associated with the use of the anti-cancer drug oxaliplatin has been reported mainly by Asiatic literature as isolate case reports. This rare but potentially fatal side effect has neither identified risk factors nor established treatment guideline. We report here a new clinical case concerning a patient with advanced gastric cancer treated with the oxaliplatin-based FOLFOX regimen along with a review of the literature as well as a discussion of emerging experimental treatment mainly based on imatinib.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22873503     DOI: 10.2174/157488612802715672

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  4 in total

Review 1.  Prognosis and treatment of FOLFOX therapy related interstitial pneumonia: a plea for multimodal immune modulating therapy in the respiratory insufficient patient.

Authors:  Annick De Weerdt; Amélie Dendooven; Annemie Snoeckx; Jan Pen; Martin Lammens; Philippe G Jorens
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

2.  A case report of acute pulmonary hypertension after hyperthermic intraperitoneal chemotherapy (HIPEC) and review of the literature.

Authors:  Thomas S Zajonz; Michael Sander; Winfried Padberg; Andreas Hecker; Ruediger Hörbelt; Christian Koch; Emmanuel Schneck
Journal:  Ann Med Surg (Lond)       Date:  2018-01-31

3.  Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin.

Authors:  Yueh-Ming Lin; Chih-I Chen; Yi-Ping Hsiang; Yung-Chia Hsu; Kung-Chuan Cheng; Pei-Hsuan Chien; Hsiao-Lin Pan; Chien-Chang Lu; Yun-Ju Chen
Journal:  Int J Mol Sci       Date:  2018-06-14       Impact factor: 5.923

4.  Evaluation of oxaliplatin-induced pulmonary toxicity in rats.

Authors:  Serdar Kalemci; Ozgür Tanrıverdi; Abdullah Şimşek; Saliha Aksun; Ozgür I Celik; Sabri Barutca; Arife Zeybek; Buket Demirci
Journal:  Contemp Oncol (Pozn)       Date:  2019-10-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.